Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
Bristol Myers Squibb, Princeton, NJ 08540, USA.
J Comp Eff Res. 2021 Apr;10(5):343-352. doi: 10.2217/cer-2020-0236. Epub 2021 Jan 14.
To compare the efficacy of nivolumab 1 mg/kg + ipilimumab 3 mg/kg with regorafenib 160 mg, cabozantinib 60 mg and nivolumab 3 mg/kg monotherapy for second-line treatment of advanced hepatocellular carcinoma. Indirect comparison using network meta-analysis and propensity score weighting. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg had significantly higher objective response rate (median 31.2% [95% credible interval: 19.6-44.5%]) than cabozantinib (4.2% [2.0-6.5%]) and regorafenib (4.8% [1.1-8.3%]), and significantly longer overall survival (cabozantinib: hazard ratio: 0.46 [95% credible interval: 0.27-0.79]; regorafenib: 0.56 [0.32-0.97]). Nivolumab 1 mg/kg + ipilimumab 3 mg/kg had significantly better objective response rate (difference 21.0% [4.5-37.5%]) and overall survival (hazard ratio: 0.58 [0.35-0.96]) than nivolumab monotherapy. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg had a superior efficacy versus cabozantinib 60 mg, regorafenib 160 mg and nivolumab 3 mg/kg monotherapy as second-line therapy for advanced hepatocellular carcinoma.
比较纳武利尤单抗 1mg/kg+伊匹单抗 3mg/kg 与regorafenib 160mg、卡博替尼 60mg 和纳武利尤单抗 3mg/kg 单药二线治疗晚期肝细胞癌的疗效。采用网络荟萃分析和倾向评分加权的间接比较。纳武利尤单抗 1mg/kg+伊匹单抗 3mg/kg 的客观缓解率（中位数 31.2%[95%可信区间：19.6-44.5%]）显著高于卡博替尼（4.2%[2.0-6.5%]）和regorafenib（4.8%[1.1-8.3%]），总生存期显著延长（卡博替尼：风险比：0.46[95%可信区间：0.27-0.79]；regorafenib：0.56[0.32-0.97]）。纳武利尤单抗 1mg/kg+伊匹单抗 3mg/kg 的客观缓解率（差异 21.0%[4.5-37.5%]）和总生存期（风险比：0.58[0.35-0.96]）均显著优于纳武利尤单抗单药治疗。纳武利尤单抗 1mg/kg+伊匹单抗 3mg/kg 作为二线治疗晚期肝细胞癌的疗效优于卡博替尼 60mg、regorafenib 160mg 和纳武利尤单抗 3mg/kg 单药治疗。
